Renephra currently have a £70k EIS investment opportunity for private investors, following an investment of £231k supported by our lead investors Deepbridge Capital and Catapult Ventures to bring us up to £300k. The minimum investment sought is £70k with an overfunding up to £330k. Find out more at https://capitalcell.co.uk/campaign/renephra/ ________ Renephra is a medical device development company developing a ground breaking technology for minimally invasive fluid removal to address the significant problems of fluid overload and chronic oedema in vascular, oncology and other disease areas. This is a substantial patient group with unmet clinical needs and is an estimated £3billion market worldwide. - Chronic Oedema is a debilitating and underestimated health problem affecting millions of people, leading to very poor quality of life, complications, frequent hospital admission and high costs of care. Currently patients' only alternative is physiotherapy, compression bandages or surgical treatment until Renephra finalizes its wearable, unobtrusive and easy-to-use device for controlled fluid removal from the skin. - Fluid overload is a major and growing problem, for example a major proportion of the 3 million renal failure patients and 26 million with heart failure suffer from fluid overload. Underlined by increasing prevalence of both diseases (8% annually), this is unsustainable and new approaches are needed urgently. Current solutions to this problem are limited. When diuretics fail, which occurs in up to 30% cases – the only other option is dialysis or ultrafiltration. These severe treatment strategies are not suitable for everyone, is debilitating and costly. The Renephra patented Fluid Removal Device uses micro-needle technology combined with negative pressure therapy to access and remove excess interstitial fluid from the skin.